Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire NEW YORK, Jan. 13, 2025...
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR...
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR...
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for...
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway...
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard®...
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services...
PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024...
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal...
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue...
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 PR Newswire NEW YORK, Oct...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 PR Newswire NEW...
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test PR...
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care PR Newswire NEW YORK...
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit PR Newswire NEW YORK, Oct. 9...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관